本文關(guān)鍵詞： 骨質(zhì)疏松癥 中風(fēng)后遺癥 泛髓關(guān)系 中醫(yī)藥治療　出處：《山東中醫(yī)藥大學(xué)》2016年碩士論文　論文類型：學(xué)位論文

【摘要】：目的:基于泛髓關(guān)系假說,探討骨質(zhì)疏松癥和中風(fēng)后遺癥的治療處方關(guān)聯(lián)性,從而為髓病的治療體系構(gòu)建提供有益參考。方法:收集整理2006-2015年間治療骨質(zhì)疏松癥和中風(fēng)后遺癥的經(jīng)驗處方,建立數(shù)據(jù)庫,運(yùn)用中醫(yī)傳承輔助系統(tǒng)分析治療兩類疾病的藥物使用規(guī)律。結(jié)果:在治療骨質(zhì)疏松癥及中風(fēng)后遺癥的前50味高頻率藥物中,有35味藥物重合,分別為白芍、白術(shù)、川芎、丹參、膽南星、當(dāng)歸、黨參、地龍、杜仲、茯苓、甘草、葛根、枸杞子、骨碎補(bǔ)、龜甲、何首烏、紅花、黃芪、雞血藤、僵蠶、龍骨、牡蠣、牛膝、全蝎、人參、山藥、山茱萸、蛇床子、生地黃、石菖蒲、熟地黃、水蛭、天麻、菟絲子、蜈蚣。在治療骨質(zhì)疏松癥及中風(fēng)后遺癥的前25味高頻率藥物中,有9味藥物重合,分別為白芍、白術(shù)、丹參、當(dāng)歸、茯苓、甘草、黃芪、牛膝、熟地黃。同時,兩者治療藥物的性味歸經(jīng)也極為相似,治療骨質(zhì)疏松癥所用的藥物中,以溫性藥物為主,其次為平、寒;以甘味藥物為主,其次為苦、辛;以入腎經(jīng)、肝經(jīng)為主,其次為脾經(jīng)、心經(jīng);在治療中風(fēng)后遺癥所用藥物中,以溫性藥物為主,其次為寒、平;以甘味藥物為主,其次為辛、苦;以入肝經(jīng)、腎經(jīng)、脾經(jīng)為主,其次為心經(jīng)。骨質(zhì)疏松癥組核心藥物有熟地黃,牛膝、淫羊藿,續(xù)斷、黃芪、杜仲、補(bǔ)骨脂、骨碎補(bǔ)、山藥。中風(fēng)后遺癥組核心藥物有當(dāng)歸、黃芪、川芎、紅花、桃仁。在常用藥對及三味藥組合方面,骨質(zhì)疏松組側(cè)重補(bǔ)益肝腎,而中風(fēng)后遺癥組則側(cè)重補(bǔ)血和益氣活血。結(jié)論:骨質(zhì)疏松癥與中風(fēng)后遺癥的中藥治療均注重補(bǔ)益氣血和活血,藥味均以甘、苦、辛為主,藥性以溫為主,歸經(jīng)以肝腎為主,提示這可能是“泛髓關(guān)系”中各類髓病的共有用藥規(guī)律之一;同時,由于當(dāng)前中風(fēng)后遺癥的治療多傾向從氣血論治,尚未從髓的角度加以系統(tǒng)總結(jié)和探討,而骨質(zhì)疏松所體現(xiàn)出的髓病治療用藥規(guī)律恰可以為中風(fēng)后遺癥的治療提供新思路,且已初步展示出良好應(yīng)有前景,有待于進(jìn)一步研究。
[Abstract]:Objective: to explore the relationship between the prescription of osteoporosis and the sequelae of apoplexy based on the hypothesis of panmedullary relationship. Methods: collecting and sorting out the experience prescriptions of treating osteoporosis and stroke sequelae from 2006 to 2015, establishing a database, Results: among the first 50 high-frequency drugs for the treatment of osteoporosis and apoplexy sequelae, 35 kinds of drugs were superimposed, namely Radix Paeoniae Alba, Radix Atractylodes macrocephala, Rhizoma Chuanxiong, Salvia miltiorrhiza, and Radix Salviae Miltiorrhizae. South Star of gallbladder, Angelica sinensis, Codonopsis, Dilong, Eucommia, Poria, Glycyrrhiza, Radix Puerariae, Fructus Lycii, Fructus Distilla, Turtle, Polygonum multiflorum, Carthamus, Astragalus, Chicken Rattan, Silkworm, Silkworm, Oyster, Oyster, Achyranthes bidentata, Scorpio, Ginseng, yam, Cornus, Cnidium cnidii, Rehmannia, Acorus calamus, Rehmannia Rehmanniae, Leech, Gastrodia elata, Cuscuta, Centipede. In the first 25 high-frequency drugs for treating osteoporosis and apoplexy sequelae, there are 9 kinds of drug superposition: Radix Paeoniae Alba, Radix Atractylodis macrocephalae, Salvia miltiorrhiza, Radix angelicae Sinensis, Poria cocos, licorice, astragalus, Achyranthes bidentata and Rehmannia glutinosa. At the same time, the quality of the drugs used for treating osteoporosis is also very similar. The second is bitter, the second is bitter; the second is the kidney meridian, the liver meridian is the main, the second is the spleen meridian, the heart meridian; in the treatment of the sequelae of apoplexy, the main medicine is the warm drug, the second is the cold, and the other is the cold, the ping; the sweet medicine is the main medicine, the second is the Xin, bitter; and the liver meridian, Kidney Meridian, spleen Meridian is dominant, followed by Heart Meridian. The core drugs in osteoporosis group are Radix Rehmanniae, Achyranthes bidentata, Herba Epimedii, Dipsacus, Astragalus, Eucommia ulmoides, Psoralen, BMD, Chinese yam. The core drugs in the apoplexy group are Angelica sinensis, Astragalus membranaceus, Ligusticum chuanxiong. Safflower, peach kernel. In the combination of common medicine and three kinds of medicine, the osteoporosis group focuses on tonifying the liver and kidney, Conclusion: the traditional Chinese medicine treatment of osteoporosis and apoplectic sequelae all pay attention to replenishing qi and promoting blood circulation, the medicine taste is mainly sweet, bitter, and Xin, the medicine is mainly warm, and the meridian is mainly liver and kidney. It is suggested that this may be one of the common drug rules of various myelopathy in the panmedullary relationship, and at the same time, because the current treatment of apoplexy sequelae tends to be based on the treatment of qi and blood, it has not been systematically summarized and discussed from the point of view of pulp. The treatment of myelopathy reflected by osteoporosis can provide a new idea for the treatment of apoplexy sequelae, and has shown a good prospect, which needs further study.
【學(xué)位授予單位】：山東中醫(yī)藥大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2016
【分類號】：R255.2

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 于光志;楊珊妹;曹宏;;基于中醫(yī)傳承輔助平臺系統(tǒng)的小兒功能性便秘組方用藥規(guī)律分析[J];湖南中醫(yī)雜志;2015年11期

2 白曉雯;;抗栓再造丸配合功能鍛煉對中風(fēng)后遺癥患者日常生活能力和生活質(zhì)量的影響[J];西部中醫(yī)藥;2015年06期

3 孫亮;;中醫(yī)治療骨質(zhì)疏松的臨床觀察[J];深圳中西醫(yī)結(jié)合雜志;2015年10期

4 趙艷青;滕晶;;基于中醫(yī)傳承輔助平臺的脅痛治療方劑組方用藥規(guī)律分析[J];中國中藥雜志;2015年06期

5 游昕;熊大國;郭志斌;商友劍;;茯苓多種化學(xué)成分及藥理作用的研究進(jìn)展[J];安徽農(nóng)業(yè)科學(xué);2015年02期

6 張蓮;郭峰;馮霞;;中醫(yī)藥防治老年骨質(zhì)疏松研究進(jìn)展[J];中國骨質(zhì)疏松雜志;2014年08期

7 杜曉麗;鄭德三;呂紅玲;;絕經(jīng)后女性骨質(zhì)疏松癥的影響因素及中醫(yī)證型分布規(guī)律初探[J];世界中醫(yī)藥;2014年06期

8 杜茂波;劉淑芝;王晨;邱東;;基于中醫(yī)傳承輔助平臺明膠軟膠囊囊皮配方規(guī)律分析[J];中國中醫(yī)藥信息雜志;2014年01期

9 左軍;張文釗;胡曉陽;馬育軒;;黃芪現(xiàn)代藥理及臨床研究進(jìn)展[J];中醫(yī)藥信息;2014年01期

10 于麗紅;劉偉;;基于“泛腦”與“泛髓”理論指導(dǎo)下的血管性認(rèn)知功能障礙發(fā)病機(jī)制探討[J];中西醫(yī)結(jié)合心腦血管病雜志;2013年10期

，

本文編號：1538146